title: Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET.
abstract: The concentration (Bmax) of the dopamine transporter (DAT) and the maximum and effective occupancies by cocaine doses of 0.1 mg/kg or 0.05 mg/kg were measured in the striatum of cocaine abusers (n = 12) by using [11C]cocaine as a radiotracer for the DAT and positron emission tomography (PET). Two methods based on a three-compartment model with one binding site (the nonlinear least squares (NLSQ) and the Farde pseudoequilibrium method) were used to estimate Bmax. Effective occupancies and maximum occupancies were calculated from the distribution volume ratios (DVR) and a three-compartment model, respectively. The NLSQ and Farde methods gave similar values of Bmax (average, 650 +/- 350 pmol/ml and 776 +/- 400 pmol/ml, respectively), but the individual estimates of Bmax were found to be very sensitive to small variations in other model parameters and were not correlated with the parameter Bmax/Kd (r = .07). The average maximum (and effective) occupancies were found to be 67% (50%) and 52% (39%) for the 0.1-mg/kg and the 0.05-mg/kg studies, respectively. The ED50 based on the effective occupancy corresponds to 0.1 mg/kg, which is significantly smaller than the ED50 of 3 mg/kg calculated from studies in which [123]beta-CIT is displaced by cocaine. The effect on the Bmax estimate of two binding sites with different Kd's is also considered by simulation. We conclude (1) that the lack of robustness in the Bmax estimate limits the usefulness of any one subject's Bmax and suggests that the combination parameter Bmax/Kd (or the DVR), which has been used extensively, is a more stable measure of free receptor/transporter concentration. The average Bmax may, however, provide an estimate of the expected concentration in humans. (2) The DVR can be used as a measure of DAT occupancy without applying an explicit model.
authors.affiliation: Chemistry Department, Brookhaven National Laboratory, Upton, New York, USA. logan@modbrain.chm.bnl.gov
authors.forename: J
authors.initials: J
authors.lastname: Logan
authors.forename: N D
authors.initials: ND
authors.lastname: Volkow
authors.forename: J S
authors.initials: JS
authors.lastname: Fowler
authors.forename: G J
authors.initials: GJ
authors.lastname: Wang
authors.forename: M W
authors.initials: MW
authors.lastname: Fischman
authors.forename: R W
authors.initials: RW
authors.lastname: Foltin
authors.forename: N N
authors.initials: NN
authors.lastname: Abumrad
authors.forename: S
authors.initials: S
authors.lastname: Vitkun
authors.forename: S J
authors.initials: SJ
authors.lastname: Gatley
authors.forename: N
authors.initials: N
authors.lastname: Pappas
authors.forename: R
authors.initials: R
authors.lastname: Hitzemann
authors.forename: C E
authors.initials: CE
authors.lastname: Shea
mesh_terms: D000328:Adult; D002250:Carbon Radioisotopes; D002352:Carrier Proteins / Q000032:analysis*; D003042:Cocaine; D019970:Cocaine-Related Disorders / Q000378:metabolism*; D003342:Corpus Striatum / Q000737:chemistry*; D050483:Dopamine Plasma Membrane Transport Proteins; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins / Q000032:analysis*; D014055:Tomography, Emission-Computed
chemical_list: D002250:Carbon Radioisotopes; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493214:SLC6A3 protein, human; D003042:Cocaine